CHMP adopts positive opinion for avapritinib for PDGFRA D842V mutant GIST
US precision therapy company Blueprint Medicines said that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion for avapritinib as a monotherapy for certain types of gastrointestinal stromal tumors (GIST). CHMP has recommended conditional marketing authorization of the kinase inhibitor in the European Union for […]
Blueprint Medicines said that the US Food and Drug Administration (FDA) has rejected its new drug application (NDA) for AYVAKIT (avapritinib) for the treatment of fourth-line gastrointestinal stromal tumor (GIST). The US precision therapy company received a complete response letter (CRL) from the FDA in this connection. Blueprint Medicines was seeking FDA approval for avapritinib […]
Continue reading …
Business News Today
- MedCrypt acquires medical device cybersecurity software firm MedISAO
- Improving acquires custom software development firm Object Partners
- High Street Insurance acquires Michigan-based Capital Insurance Group
- Mill Creek Residential breaks ground on Modera Washington in Houston
- Cincinnati-based RIA Lenox Wealth Management acquired by Creative Planning
- Jersey Elevator acquired by Arcline Investment Management
- U.S. Gold acquires Northern Panther Resource, owner of Challis gold project
- Perrigo acquires skincare and hair loss treatment brands from Sanofi
- Bayer to acquire KaNDy Therapeutics to add menopause drug candidate
- Thoma Bravo to acquire US insurtech Majesco for higher price of $729m
